Regeneron Pharmaceuticals Inc. buy Wells Fargo & Company
Summary
This prediction is currently active. With a performance of -6.55%, the BUY prediction by Wells_Fargo___Compan is trending in the wrong direction. This prediction currently runs until 23.09.25. The prediction end date can be changed by Wells_Fargo___Compan at any time. Wells_Fargo___Compan has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w |
---|---|
Regeneron Pharmaceuticals Inc. | -6.55% |
iShares Core DAX® | 1.518% |
iShares Nasdaq 100 | 1.240% |
iShares Nikkei 225® | 2.808% |
iShares S&P 500 | 0.403% |
Comments by Wells_Fargo___Compan for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
02.08.24
02.08.25
26.09.24